Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.71+0.64 (+4.90%)
At close: 04:00PM EDT
13.71 0.00 (0.00%)
After hours: 04:15PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • j
    james
    Elucidates the importance of Safety. $KURA $AGIO would give an arm and a leg for Gps $SLS https://www.fiercebiotech.com/biotech/fda-tacks-full-clinical-hold-foghorn-trial-clouded-more-patient-deaths
    "For the sickest patients, GPs therapy includes no side affects beyond standard vaccination flu like symptoms as patient's own immune systems are activated and super charged to kill WT1 cancer cells."
  • s
    semmens
    I am staying far away from KURA - It looks like it is going to drop off a cliff. I actually get way better stocks at (http://Themaxgains.tech)
  • H
    Hector
    im still waiting for this stock to go up,
  • B
    Breezy
    Anybody home? This is weird.
  • C
    Cured
    $SLS conversation
    more tough news for AML patients
    FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death
    by Kyle LaHucik | Nov 24, 2021 9:55am FDA Building 2
    The cause of death in Kura Oncology's early-stage cancer trial, differentiation syndrome, is seen in some treatments for acute myeloid leukemia (AML) and was included in the black box warning of an AML drug approved by the FDA in 2018. (FDA)
    The FDA sidelined an early-stage cancer trial from $Kura Oncology after a patient died due to a serious adverse event related to the oral treatment's mechanism of action.

    The partial clinical hold means no additional patients in the acute myeloid leukemia trial will be enrolled until the FDA gives the green light. The regulator's information request is "not complicated," and the hold should be "relatively short," Kura's management said in a conference call Wednesday morning.

    Kura's stock was down 22% to $12.95 a share as of 9:30 a.m. ET.
    Bullish
  • S
    Sharon
    company just announced on very exciting and encouraging results!!!
    Bullish
  • S
    StockScreenerTips
    $KURA stock up a hugh 43%. No obvious news, so could be related to good news for "Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas".
    https://twitter.com/DanShane777/status/1255168887999660033
    “$KURA #stock up a hugh 43%. No obvious news, so could be related to good news for "Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas". Link: https://t.co/OPEUO8RpY5 #biotech #stockstowatch #stockmarkets”
    “$KURA #stock up a hugh 43%. No obvious news, so could be related to good news for "Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas". Link: https://t.co/OPEUO8RpY5 #biotech #stockstowatch #stockmarkets”
    twitter.com
  • H
    Hector
    i will buy @ 10.00
  • A
    Anonymous
    Those CR's in heavily pre-treated patients looks very good. Expect move in pre-Market.
  • A
    Are
    Looks like the trials are going well.
  • d
    david
    did the drug trial fail? why did someone invest $1.5 Million on the puts
  • C
    Crescent
    Over reaction to earnings
  • d
    david
    KO-539 is the winner in here...if all goes at plan $50 stock
    Bullish
  • C
    Crescent
    Something in the works
  • A
    Alex
    FDA’s Fast Track designation puts us one step closer to delivering a precision medicine treatment for patients with this devastating disease. This is going to fly to 100+ in the next few years
    Bullish
  • a
    adityap
    Added 50k today. Monday here it comes $20
  • K
    Ken
    Up almost 50% on no news. Hmmm!
Advertisement
Advertisement